Injectsense announced completion of a successful in-vivo animal study of the first implantable sensor and monitoring system designed to collect long-term IOP data. The Injectsense IOP-Connect system creates an organ-to-cloud data connection that enables the clinician to assess glaucoma therapy effectiveness at any time. The system is expected to provide visibility into the IOP profile of the patient over time, and into previously unobserved changes that may affect glaucoma progression, according to a company news release.
As part of the study, researchers at an accredited US research organization were able to implant the self-anchoring sensor safely and collect accurate pressure readings–in agreement with tonometry measurements–for the week-long test period. No device-related adverse events were reported.
“One of the challenges in addressing glaucoma is the lack of visibility into continuous IOP changes,” Myron Yanoff, MD, FAAO, Chair Emeritus, Department of Ophthalmology at Drexel University and Adjunct Professor, Department of Ophthalmology at the University of Pennsylvania, said in the news release. “The product being developed by Injectsense is a game changer in how and when to regulate the treatment of glaucoma. It offers a tangible path to clinically actionable information, enabling new insights into the true relationship between IOP, glaucoma, and therapy effectiveness. It also opens a world of possibilities into basic research on the inherent changes in the mechanisms of glaucoma.”
Beyond ophthalmology, the sensor-enabled digital health platform is versatile, potentially enabling diagnostic and therapeutic applications in many different domains, from intracranial, urological, and various cardiovascular pressure parameters to neurosurgery and fluidic applications.